153 related articles for article (PubMed ID: 19835018)
1. Legal and economic perspectives concerning US government investigations of alleged off-label promotion by drug manufacturers.
Kalb PE; Greenberg PE
Pharmacoeconomics; 2009; 27(8):623-5. PubMed ID: 19835018
[No Abstract] [Full Text] [Related]
2. Pros and cons of off-label promotion investigations and prosecutions.
Loucks MK
Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
[No Abstract] [Full Text] [Related]
3. Tort claims and federal regulation of medical devices vs pharmaceuticals.
Green M
JAMA; 2009 Sep; 302(11):1169; author reply 1169-70. PubMed ID: 19755694
[No Abstract] [Full Text] [Related]
4. Shifting terrain in the regulation of off-label promotion of pharmaceuticals.
Mello MM; Studdert DM; Brennan TA
N Engl J Med; 2009 Apr; 360(15):1557-66. PubMed ID: 19357413
[No Abstract] [Full Text] [Related]
5. Regulating the safety of pharmaceuticals: the FDA, preemption, and the public's health.
Gostin LO
JAMA; 2009 May; 301(19):2036-7. PubMed ID: 19454642
[No Abstract] [Full Text] [Related]
6. The federal preemption debate in pharmaceutical labeling product liability actions.
Gross JM; Curry JA
Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
[No Abstract] [Full Text] [Related]
7. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2010 Jan; ():1-31. PubMed ID: 20217914
[No Abstract] [Full Text] [Related]
8. Off-label or off-limits?
Ratner M; Gura T
Nat Biotechnol; 2008 Aug; 26(8):867-75. PubMed ID: 18688236
[No Abstract] [Full Text] [Related]
9. Good law from tragic facts--Congress, the FDA, and preemption.
Annas GJ
N Engl J Med; 2009 Sep; 361(12):1206-11. PubMed ID: 19759383
[No Abstract] [Full Text] [Related]
10. Off-label or out of bounds? Prescriber and marketer liability for unapproved uses of FDA-approved drugs.
O'Reilly J; Dalal A
Ann Health Law; 2003; 12(2):295-324, table of contents. PubMed ID: 12856461
[TBL] [Abstract][Full Text] [Related]
11. Pfizer to pay $430 million over promoting drug to doctors.
Harris G
N Y Times Web; 2004 May; ():C6. PubMed ID: 15290803
[No Abstract] [Full Text] [Related]
12. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
Gitter DM
Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
[No Abstract] [Full Text] [Related]
13. Prescription drugs marketed in the United States should be approved by the FDA.
Shepherd MD; Curtiss FR
J Manag Care Pharm; 2003; 9(4):366-7. PubMed ID: 14613456
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceuticals and medical devices: FDA oversight.
Berry MD
Issue Brief Health Policy Track Serv; 2013 Dec; ():1-123. PubMed ID: 24482893
[No Abstract] [Full Text] [Related]
15. Off-label marketing and the First Amendment.
Boumil MM
N Engl J Med; 2013 Jan; 368(2):103-5. PubMed ID: 23234470
[No Abstract] [Full Text] [Related]
16. Clinical trial transparency--antidote to weaker off-label-promotion rules?
Outterson K
N Engl J Med; 2014 Jul; 371(1):1-3. PubMed ID: 24988551
[No Abstract] [Full Text] [Related]
17. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
Thomson Reuters/West
Issue Brief Health Policy Track Serv; 2011 Jan; ():1-39. PubMed ID: 21374841
[No Abstract] [Full Text] [Related]
18. Regulatory experts debate FDA's authority.
Young D
Am J Health Syst Pharm; 2007 May; 64(9):910, 912. PubMed ID: 17468140
[No Abstract] [Full Text] [Related]
19. US drug regulator warns manufacturers that it will not accept data from Indian research center.
Dyer O
BMJ; 2016 Apr; 353():i2476. PubMed ID: 27130404
[No Abstract] [Full Text] [Related]
20. Regulating Off-Label Promotion - A Critical Test.
Robertson C; Kesselheim AS
N Engl J Med; 2016 Dec; 375(24):2313-2315. PubMed ID: 27805841
[No Abstract] [Full Text] [Related]
[Next] [New Search]
